Search

Highlights of Past EHA - Cairo 2017

Dates: September 14 - 15, 2017
Location: Cairo, Egypt
Chairs: 
Prof Azza Kamel, Secretary General, Egyptian Society of Hematology and Research (ESHR)
Prof Amal El-Beshlawy, Vice President, Egyptian Society of Hematology and Research (ESHR)
Prof John Gribben, President elect, European Hematology Association (EHA)
Prof Mohamad Qari, President, Pan…

Read more

EHA-SWG Scientific Meeting "Patient-centered Geriatric Hematology"

EHA & the EHA Scientific Working Group on Hematology and Aging are happy to announce their recent collaboration in organizing a virtual meeting program providing delegates with the latest insights in the field of geriatric hematology, presented by leading hematologists.

Read more

Highlights from the SWG

SWG Committee meetingsIn 2023, the SWG Committee held meetings on:

February 21, 2023—online
April 6, 2023—in The Hague
June 8, 2023—at the EHA Congress 2023 in Frankfurt
In addition, an SWG Chairs and Committee Meeting was held on September 29, 2023, in The Hague.…

Read more

The HARMONY project: learning to work in BIG (DATA) teams

The HARMONY project: learning to work in BIG (DATA) teams

By Anna Kabanova PhD, YoungEHA committee member

On 26 and 27 September 2019 several YoungEHA members, including myself, had the chance to participate in the 4th General Assembly of the HARMONY Alliance…

Read more

Publications

The publications of the ESLHO networks can be found on the following pages:

EuroFlow publications
EuroMRD publications
EuroClonality publications
The publications from 2023 are also listed below.

Read more

EHA returns to Cairo with the Highlights of the 24th EHA Congress

The 4th Highlights of Past EHA (HOPE) Middle East & North Africa (MENA) took place (for the third time) in Cairo, Egypt, organized in collaboration with the Pan Arab Hematology Association (PAHA) and hosted by the Egyptian Society of Hematology…

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more